Document Detail

DNA polymorphisms of apolipoprotein B and AI/CIII genes and response to gemfibrozil treatment.
MedLine Citation:
PMID:  1678324     Owner:  NLM     Status:  MEDLINE    
Apolipoprotein B XbaI polymorphism and apolipoprotein AI/CIII SstI polymorphism have been found to be associated with variations in serum lipoprotein levels. We investigated whether these gene polymorphisms are involved in determining the lipid-modulating action of gemfibrozil. Of the 221 male subjects with hyperlipidemia studied, 121 responded well to the treatment with more than a 25% reduction in the non-high-density lipoprotein cholesterol level, whereas 100 were nonresponders. Among responders, but not nonresponders, homozygosity for the apolipoprotein B X2 allele (XbaI site present) and heterozygosity for the apolipoprotein AI/CIII S2 allele (SstI site present) were associated with elevated baseline serum low-density lipoprotein cholesterol and triglyceride levels, respectively. However, the hypolipidemic effect of gemfibrozil among the responders was independent of these gene polymorphisms. These data indicate that common polymorphisms of the apolipoprotein B and apolipoprotein AI/CIII gene loci influence serum lipid levels by mechanisms that are amenable to an intervention with gemfibrozil.
K Aalto-Setälä; K Kontula; M Mänttäri; J Huttunen; V Manninen; P Koskinen; H M Frick
Related Documents :
11122694 - Common mutations of the lipoprotein lipase gene and their clinical significance.
11793484 - Seven novel sequence variants in the human low density lipoprotein receptor related pro...
15654334 - Low ldl cholesterol in individuals of african descent resulting from frequent nonsense ...
24045484 - Selection of snps from 50k and 777k arrays to predict breed-of-origin in cattle.
17514784 - Multilocus mutation scanning for the analysis of genetic variation within malassezia (b...
23180144 - Hiv drug resistance and the advent of integrase inhibitors.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  50     ISSN:  0009-9236     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  1991 Aug 
Date Detail:
Created Date:  1991-09-16     Completed Date:  1991-09-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  208-14     Citation Subset:  AIM; IM    
Institute of Biotechnology, University of Helsinki, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apolipoprotein A-I
Apolipoprotein C-III
Apolipoproteins A / genetics*
Apolipoproteins B / genetics*
Apolipoproteins C / genetics*
Cholesterol, HDL / blood,  drug effects
Cholesterol, LDL / blood,  drug effects
DNA / drug effects*,  genetics
Gemfibrozil / pharmacology*
Middle Aged
Polymorphism, Restriction Fragment Length
Triglycerides / blood
Reg. No./Substance:
0/Apolipoprotein A-I; 0/Apolipoprotein C-III; 0/Apolipoproteins A; 0/Apolipoproteins B; 0/Apolipoproteins C; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Triglycerides; 25812-30-0/Gemfibrozil; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Despite expression in embryonic visceral mesoderm, H2.0 is not essential for Drosophila visceral mus...
Next Document:  New prospects in the therapeutic use of somatostatin and its derivatives